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We read with interest the article by Signorelli et al entitled "Plasma Levels of Inflammatory Biomarkers in Peripheral Arterial Disease: Results of a Cohort Study." 1 They reported that higher plasma levels of inflammatory biomarkers were related to the development of peripheral arterial disease (PAD). 1 The cause of PAD is usually atherosclerosis.
2, 3 Signorelli et al analyzed several inflammation biomarkers (eg, interleukin 6, tumor necrosis factor a, L-selectin, neopterin, P-selectin, E-selectin, vascular cell adhesion molecule 1, intercellular adhesion molecule 1, and matrix metalloproteinases 2 and 9) in patients with PAD, and all results were statistically significant. 1 Perhaps, some of the basic and cheaper methods like C-reactive protein, neutrophil to lymphocyte ratio, and so on, could be analyzed 4 ; however, this comprehensive profile is better.
In their article, they stated "Reducing the high plasma levels of inflammatory markers may be effective in preventing the progression of atherosclerosis and improving clinical outcome in patients with PAD."
1 Indeed, PAD and atherosclerosis occur together with an inflammation process. [4] [5] [6] Signorelli et al and Li et al have reviewed the relationship between inflammation and PAD. [7] [8] [9] Also, there are some big studies supporting this conclusion and showing that reducing the levels of biomarkers is associated with better outcome. 10, 11 On the other hand, there are some trials that tried to treat these patients with atherosclerosis with anti-inflammatory drugs and resulted in failure. 12, 13 As these trials resulted in failures, if we aimed to selectively decrease inflammation molecules, it may cause other problems like immune deficiency. 12, 13 Which process started first and which process can stop the other? Appropriate treatment usually involves addressing the underlying cause of inflammation. So, here, inflammation biomarkers were probably elevated as a response to PAD which involves the vessel wall, like all other atherosclerosis 2, 3 ; on the other hand, several biomarkers in the article 1 are adhesion molecules which ensure rolling and migration to cells in blood.
14 Thus, if we target biomarkers instead of the responsible disease, we may not succeed. We should treat PAD appropriately, then biomarkers will decrease on their own.
In conclusion, plasma inflammation biomarkers could be useful for predicting PAD. However, we may not be able to treat atherosclerosis, including PAD, by selectively reducing biomarker levels. We may need treatments like statins which decrease inflammation as well as atherosclerosis as suggested by Signorelli et al. 
